The AACU Supports Federal Funding for the Kidney Cancer Research Program (KCRP)
The AACU joined thirteen other organizations in asking the House and Senate appropriations committees to allocate $60 million in FY24 for the Kidney Cancer Research Program (KCRP) at the Congressionally Directed Medical Research Programs (CDMRP) conducted by the US Department of Defense. The CDMRP’s highly innovative research drives scientific discovery in high-impact research areas, (including kidney cancer) not sponsored by the National Institutes of Health (NIH) and other federal agencies.
FDA expert reviews data supporting belzutifan approval for VHL-associated kidney cancer
November 16th 2023Data from the phase 2 LITESPARK-004 trial led to the FDA approval of belzutifan for patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma and other diseases.
CAR T-cell therapy explored as potential option for advanced renal cell carcinoma
November 13th 2023Researchers are exploring the potential of CAR T-cell therapy in patients with renal cell carcinoma who have disease progression following treatment with checkpoint inhibitors and VEGF inhibitors.
Adjuvant pembrolizumab improves overall survival in certain patients with renal cell carcinoma
November 1st 2023Adjuvant pembrolizumab improved overall survival compared with placebo in patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Phase 3 trial of subcutaneous nivolumab in ccRCC meets co-primary end points
October 19th 2023Data showed noninferiority of subcutaneous nivolumab to intravenous nivolumab in the time-average to nivolumab serum concentration over 28 days (Cavgd28) and the trough serum concentration at steady state (Cminss).
